Related references
Note: Only part of the references are listed.Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
Diego Chowell et al.
SCIENCE (2018)
High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma
Alexander T. Faje et al.
CANCER (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary
Julie R. Brahmer et al.
JOURNAL OF ONCOLOGY PRACTICE (2018)
Synthetic immune niches for cancer immunotherapy
Jorieke Weiden et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
A. M. Menzies et al.
ANNALS OF ONCOLOGY (2017)
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab
N. Chaput et al.
ANNALS OF ONCOLOGY (2017)
Coinhibitory Pathways in Immunotherapy for Cancer
Susanne H. Baumeister et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 34 (2016)
Cancer immunotherapy: the beginning of the end of cancer?
Sofia Farkona et al.
BMC MEDICINE (2016)
CD28 Costimulation: From Mechanism to Therapy
Jonathan H. Esensten et al.
IMMUNITY (2016)
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg et al.
LANCET (2016)
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
Sarah B. Goldberg et al.
LANCET ONCOLOGY (2016)
Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
Krista Dubin et al.
NATURE COMMUNICATIONS (2016)
Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab
Camille Hua et al.
JAMA DERMATOLOGY (2016)
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Douglas B. Johnson et al.
JAMA ONCOLOGY (2016)
Systematic review: colitis associated with anti-CTLA-4 therapy
A. Gupta et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
Padmanee Sharma et al.
CELL (2015)
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Antoni Ribas et al.
LANCET ONCOLOGY (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Immune Escape Mechanisms as a Guide for Cancer Immunotherapy
Gregory L. Beatty et al.
CLINICAL CANCER RESEARCH (2015)
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
Bruno Sangro et al.
JOURNAL OF HEPATOLOGY (2013)
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial
Luana Calabro et al.
LANCET ONCOLOGY (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Programmed death-1 gene polymorphism (PD-1.5 C/T) is associated with colon cancer
Zahra Mojtahedi et al.
GENE (2012)
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Ipilimumab in advanced melanoma: reports of long-lasting responses
Alberto Farolfi et al.
MELANOMA RESEARCH (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Phase II Study of the Anti-Cytotoxic T-Lymphocyte-Associated Antigen 4 Monoclonal Antibody, Tremelimumab, in Patients With Refractory Metastatic Colorectal Cancer
Ki Y. Chung et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412
Ganesh Suntharalingam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
What is the importance of the immunological synapse?
DM Davis et al.
TRENDS IN IMMUNOLOGY (2004)
Cancer immunoediting: from immunosurveillance to tumor escape
GP Dunn et al.
NATURE IMMUNOLOGY (2002)
The interaction properties of costimulatory molecules revisited
AV Collins et al.
IMMUNITY (2002)